{"nctId":"NCT00527605","briefTitle":"Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)","startDateStruct":{"date":"2007-10"},"conditions":["Benign Prostatic Hyperplasia","Prostatic Hyperplasia"],"count":253,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Dutasteride 0.5mg capsule"]},{"label":"B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Dutasteride matched placebo"]}],"interventions":[{"name":"Dutasteride 0.5mg capsule","otherNames":[]},{"name":"Dutasteride matched placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion:\n\n* Clinical diagnosis of BPH\n* AUA-SI \\>=12 \\[American Urological Association Symptom Index\\]\n* Qmax \\> 5ml/sec and \\<=15ml/sec and minimum voided volume of \\>=125ml\n* Prostate volume \\>=30cm(3)\n\nExclusion:\n\n* Post void residual volume \\>250ml\n* History or evidence of prostate cancer\n* Total serum PSA \\<1.5ng/ml or \\>10.0ng/ml (Prostate specific antigen)\n* Previous prostatic surgery or other invasive procedures to treat BPH.\n* History of AUR (Acute Urinary Retention) within 3 months\n* History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7 days\n* Any causes other than BPH, which may in the judgement of the investigator, result in urinary symptoms or changes in flow rate\n* History of hepatic impairment or abnormal liver function tests\n* Use of any 5a-reductase inhibitors ,any drugs with antiandrogenic properties or other drugs noted for gynaecomastia effects, or could affect prostate volume, within past 6 months and throughout the study\n* Use of alpha-receptor blockers within 2 weeks and throughout the study.\n* Use of phytotherapy for BPH within 2 weeks and/or predicted to need phytotherapy during the study.\n* Concurrent use of anabolic steroids\n* Use of any alpha-adrenergic agonists or cholinergics within 48 hours prior to uroflowmetry assessment.\n* Hypersensitivity to any 5a-reductase inhibitor or other chemically-related drugs.\n* Actively trying to procreate or unwilling to wear a condom during intercourse with a woman of childbearing potential for duration of participation in this study and 16 weeks following treatment.\n* History or current evidence of drug or alcohol abuse within the previous 12 months.\n* History of any illness that in the opinion of the investigator might confound the results of the study or poses additional risk to the patient.\n* Any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, of cerebrovascular accident within 6 months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management.\n* History of renal insufficiency, or serum creatinine \\>1.5xULN (Upper Limit of Normal )\n* Participation in any investigational or marketed drug trial within 30 days and during the course of the study.","healthyVolunteers":false,"sex":"MALE","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in the Prostate Volume at Month 6","description":"Percent change from baseline was calculated as the prostate volume at Month 6 minus the volume at baseline, divided by the prostate volume at baseline and multiplied by 100. Prostate volume was measured by transrectal ultrasound.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.00","spread":"21.41"},{"groupId":"OG001","value":"-2.77","spread":"24.96"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Prostate Volume at Month 3","description":"Percent change from baseline was calculated as the prostate volume at Month 3 minus the volume at baseline, divided by the prostate volume at baseline and multiplied by 100. Prostate volume was measured by transrectal ultrasound.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.02","spread":"23.22"},{"groupId":"OG001","value":"-1.02","spread":"25.79"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Prostate Volume at Month 6","description":"Change from baseline was calculated as the prostate volume at Month 6 minus the volume at baseline. Prostate volume was measured by transrectal ultrasound.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.16","spread":"12.74"},{"groupId":"OG001","value":"-1.20","spread":"12.77"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Prostate Volume at Month 3","description":"Change from baseline was calculated as the prostate volume at Month 3 minus the volume at baseline. Prostate volume is measured by transrectal ultrasound.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.11","spread":"13.02"},{"groupId":"OG001","value":"-1.06","spread":"11.48"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Serum Dihydrotestosterone (DHT) at Month 6","description":"Percent change from baseline was calculated as serum DHT at month 6 minus the value at baseline ,divided by the baseline value and multiplied by 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.53","spread":"44.42"},{"groupId":"OG001","value":"26.78","spread":"149.07"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Serum DHT at Month 3","description":"Percent change from baseline was calculated as the DHT at Month 3 minus the value at baseline, divided by the baseline value and multiplied by 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.15","spread":"37.90"},{"groupId":"OG001","value":"28.33","spread":"133.71"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Serum DHT at Month 6","description":"Change from baseline was calculated as the value of DHT at Month 6 minus the baseline value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-289.175","spread":"270.610"},{"groupId":"OG001","value":"-46.099","spread":"399.806"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Serum DHT at Month 3","description":"Change from baseline was calculated as the value of DHT at Month 3 minus the baseline value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-319.605","spread":"256.058"},{"groupId":"OG001","value":"-34.400","spread":"399.633"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the American Urological Association Symptom Index (AUA-SI) Score at Month 6","description":"Percent change from baseline is calculated as the AUA-SI score at month 6 minus the baseline AUA-SI score, divided by the baseline score and multiplied by 100. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.48","spread":"26.01"},{"groupId":"OG001","value":"-20.79","spread":"30.18"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the AUA-SI Score at Month 3","description":"Percent change from baseline is calculated as the AUA-SI score at month 3 minus the baseline AUA-SI score, divided by the baseline score and multiplied by 100. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.64","spread":"24.59"},{"groupId":"OG001","value":"-11.91","spread":"21.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the AUA-SI Score at Month 6","description":"Change from baseline was calculated as the AUS-SI score at month 6 minus the baseline score. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"4.8"},{"groupId":"OG001","value":"-4.1","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the AUA-SI Score at Month 3","description":"Change from baseline was calculated as the AUA-SI score at month 3 minus the baseline score. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostate hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"3.9"},{"groupId":"OG001","value":"-2.4","spread":"3.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Maximum Urinary Flow Rate (Qmax) at Month 6","description":"Percent change from baseline was calculated as Qmax at Month 6 minus Qmax at baseline, divided by baseline Qmax and multiplied by 100. Qmax is the peak urinary flow measured by a uroflow meter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.14","spread":"57.43"},{"groupId":"OG001","value":"6.31","spread":"47.55"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Qmax at Month 3","description":"Percent change from baseline was calculated as Qmax at Month 3 minus Qmax at baseline, divided by baseline Qmax and multiplied by 100. Qmax is the peak urinary flow measured by a uroflow meter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.34","spread":"42.86"},{"groupId":"OG001","value":"5.85","spread":"34.69"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Qmax at Month 6","description":"Change from baseline was calculated as Qmax at Month 6 minus Qmax at baseline. Qmax is the peak urinary flow measured by a uroflow meter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"5.61"},{"groupId":"OG001","value":"0.03","spread":"5.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Qmax at Month 3","description":"Change from baseline was calculated as Qmax at Month 3 minus Qmax at baseline. Qmax is the peak urinary flow measured by a uroflow meter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"4.74"},{"groupId":"OG001","value":"0.17","spread":"4.56"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":126},"commonTop":["Upper respiratory tract infection","Stomach discomfort","Nasopharyngitis","Back pain","Libido decreased"]}}}